Cigna earnings beat by $0.04, revenue topped estimates
SAN DIEGO - Ainos, Inc. (NASDAQ:AIMD), a micro-cap technology company currently valued at approximately $11 million, announced Tuesday that its partner ugo, Inc. will deploy robots equipped with AI Nose technology at seven industrial sites across Japan, marking what the company calls the first service robots with a sense of smell. According to InvestingPro data, the stock has experienced significant volatility, declining nearly 28% over the past six months.
The robots will operate in pharmaceutical manufacturing, facility management, energy operations, power substations, and water treatment plants operated by Japanese corporations, according to a company press release.
"By giving robots the sense of smell, we are redefining how machines perceive and respond to the world," said Eddy Tsai, Chairman, President, and CEO of Ainos.
The deployment represents part of Ainos’ 90-day action plan, which also includes completing pilot deployment of approximately 1,400 AI Nose units with ASE Technology Holding and beginning Phase 1 expansion to approximately 5,000 units.
Ainos reports that in prior validations, its AI Nose delivered approximately 80% accuracy across 22 industrial scent types at Japanese semiconductor facilities and achieved approximately 85% accuracy in hygiene-focused senior care pilots in Japan.
The company’s technology combines MEMS sensor arrays with AI algorithms to detect scents and convert them into what it calls "Smell ID" data. Ainos plans to offer this as a subscription-based service.
According to the press release, the global electronic nose market is projected to grow from $29.79 billion in 2025 to $76.45 billion by 2032, with industrial applications representing the largest segment.
Ainos, which trades on Nasdaq under the ticker AIMD, describes itself as a dual-platform AI and biotech company developing both smell technology and immune therapeutics.
In other recent news, Ainos, Inc. has reported its first revenue from the deployment of its AI Nose technology in Japan’s senior care sector, with first-quarter revenue increasing by 412% year-over-year. The company also received regulatory approval in Taiwan to begin human clinical trials for its VELDONA oral interferon treatment, targeting HIV-related oral warts and primary Sjögren’s syndrome, with patient enrollment anticipated in the latter half of 2025. Ainos has completed a 1-for-5 stock consolidation, a move aimed at attracting institutional investors and maintaining its Nasdaq listing. This consolidation reduces the number of outstanding shares, proportionally increasing the share price while keeping shareholder ownership percentages unchanged.
Additionally, Ainos has partnered with Taiwan-based Kenmec Mechanical Engineering Co., Ltd. to expand its AI Nose and smell language model technologies for industrial applications. Kenmec will receive a commercial license to incorporate AI Nose into automation solutions, with plans to showcase these technologies at Automation Taipei 2025 in August. The AI Nose platform has shown significant progress in detecting excretion odors in elder care, achieving an accuracy rate of approximately 85%. This advancement positions Ainos as a potential leader in the emerging SmellTech market, with the technology being ready for integration into various devices and systems.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.